Amgen Inc.

As of June 30, 2026, Amgen Inc. carries a market capitalization of 170.83B, placing it among publicly traded companies globally. Its enterprise value stands at 208.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Amgen Inc.'s next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Amgen Inc. has 540.60M shares outstanding.

As of June 30, 2026, Amgen Inc. trades at a trailing price-to-earnings ratio of 22.27. The price-to-sales ratio is 5.11, and the price-to-book ratio stands at 16.70.

As of June 30, 2026, Amgen Inc. trades at an EV/EBITDA multiple of 14.82 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 20.87 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Amgen Inc. trades at an EV/FCF ratio of 19.17, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 208.74B versus a market cap of 170.83B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Amgen Inc. maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 490.28, indicating elevated leverage, while an interest coverage ratio of 6.03 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Amgen Inc. posted a return on equity (ROE) of 91.47, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 14.64 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.53, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.60, useful for judging operating efficiency across full business cycles. The company generates approximately 1.09M in revenue per employee across its workforce of 30,625.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.81 indicates how many times Amgen Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Amgen Inc. recorded 1.35B in income tax expense. That works out to an effective tax rate of 15.01, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 9.00B, leaving 7.65B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Amgen Inc.'s stock has gained approximately 50.07% over the past 52 weeks. The 50-day moving average sits at 363.42, while the 200-day moving average is 320.79.

Over the twelve months ended June 30, 2026, Amgen Inc. generated 33.34B in revenue and converted that into 7.65B in net income, yielding earnings per share of 14.09. EBITDA reached 14.09B, while operating income came in at 10.00B.

As of June 30, 2026, Amgen Inc. holds 12.24B in cash and equivalents against 50.16B in total debt, resulting in a net debt position of 37.91B. Total book value stands at 10.23B, with working capital of 8.28B providing operational flexibility.

Amgen Inc. produced 10.92B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.02B in capital expenditures, free cash flow totaled 8.91B - equivalent to 16.52 per share.

Over the twelve months ended June 30, 2026, Amgen Inc. posted a gross margin of 69.52, reflecting its pricing power and cost economics. The operating margin of 29.99 and net profit margin of 22.95 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Amgen Inc. paid dividends of 8.58 per share. The dividend payout ratio of 60.45 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.19, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.11, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Amgen Inc. shareholders.

Amgen Inc.'s most recent stock split took place on November 22, 1999 with a 1:2 split ratio.

As of June 30, 2026, Amgen Inc. has an Altman Z-Score of 2.39, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.